Biosense Webster Offers NaviStar ThermoCool Catheter


February 6, 2009

Biosense Webster Inc. offers the NaviStar ThermoCool Catheter for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used with compatible 3D electroanatomic mapping systems.

It is first and only ablation catheter in the U.S. to be approved for the treatment of this disorder. The NaviStar ThermoCool Catheter is also approved in the U.S. for the treatment of Type 1 atrial flutter, and recurrent drug/device refractory sustained monomorphic ventricular tachycardia due to prior myocardial infarction (heart attack). Atrial flutter and ventricular tachycardia are two types of cardiac arrhythmia.

The device was FDA approved in February 2009.